Agios (Nasdaq: AGIO) lifts Q2 2026 revenue but posts loss
Rhea-AI Filing Summary
Agios Pharmaceuticals reported second-quarter 2026 results highlighted by sharp growth in mitapivat revenue. Worldwide net revenues from PYRUKYND and AQVESME were $44.7 million, up from $12.5 million a year earlier. Net loss was $100.7 million, compared to $112.0 million, or $1.69 per share.
U.S. mitapivat revenue reached $40.9 million and ex-U.S. revenue $3.8 million, with 442 cumulative AQVESME prescriptions for thalassemia written by REMS‑certified U.S. physicians. PYRUKYND received European Commission marketing authorization for thalassemia, and mitapivat is now approved for adults with thalassemia in the U.S., Saudi Arabia, United Arab Emirates, and EU.
The FDA accepted Agios’ sNDA for mitapivat in sickle cell disease with Priority Review and a November 1, 2026 PDUFA goal date, and the first patient was dosed in the REIGNITE Phase 3 trial. Agios licensed cevidoplenib for immune thrombocytopenia, advanced AG‑236 toward Phase 2/3 in polycythemia vera and AG‑181 in PKU, discontinued tebapivat programs, and ended the quarter with $964.8 million in cash, cash equivalents and marketable securities.
Positive
- Net product revenue grew to $44.7 million in Q2 2026 from $12.5 million in Q2 2025, while net loss narrowed to $100.7 million from $112.0 million, indicating early operating leverage as the mitapivat franchise scales.
- Mitapivat’s sNDA in sickle cell disease received FDA Priority Review with a PDUFA goal date of November 1, 2026, creating a clear potential timeline for expansion into a new, larger indication.
- The EC granted marketing authorization for PYRUKYND in thalassemia, making it the only medicine approved across all EU member states for this broad patient population, expanding Agios’ international commercial footprint.
- Agios reported $964.8 million in cash, cash equivalents and marketable securities as of June 30, 2026, and stated that, together with anticipated product revenue and interest income, this is expected to provide financial independence for planned launches and pipeline development.
Negative
- Agios remains unprofitable, recording a Q2 2026 net loss of $100.7 million and first-half 2026 net loss of $199.8 million, driven by high R&D and SG&A spending to support its pipeline and commercial launches.
- The company will not advance tebapivat in lower-risk myelodysplastic syndromes or sickle cell disease after Phase 2 studies failed to show sufficient clinical benefit or differentiation, reducing the breadth of its development pipeline.
Filing Explained
The release is furnished rather than filed under Section 18, while reported liquidity fell from $1.2 billion at year-end to $964.8 million.
This Form 8-K reports Agios’s second-quarter results and business updates through a press release furnished as Exhibit 99.1 on
The release describes Agios as “well capitalized,” while reporting
At
Sources and calculations
- Agios Pharmaceuticals Form 8-K and Exhibit 99.1 (2026-07-30)
- Form 8-K purpose (current)
- Agios first-quarter 2026 fundamentals (2026-03-31)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $113,600,000 / ($118,920,000 / 90) = [object Object]
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Worldwide mitapivat net revenue Q2 2026: $44.7 million
U.S. mitapivat net revenue Q2 2026: $40.9 million
Ex-U.S. mitapivat net revenue Q2 2026: $3.8 million
+5 more
8 metrics
Worldwide mitapivat net revenue Q2 2026
$44.7 million
Worldwide net revenues of PYRUKYND and AQVESME in the second quarter of 2026
U.S. mitapivat net revenue Q2 2026
$40.9 million
U.S. net revenue from mitapivat in the second quarter of 2026
Ex-U.S. mitapivat net revenue Q2 2026
$3.8 million
Ex-U.S. net revenue from mitapivat in the second quarter of 2026
Net loss Q2 2026
$100.7 million
Net loss for the quarter ended June 30, 2026
Cash, cash equivalents and marketable securities
$964.8 million
Balance as of June 30, 2026
R&D expenses Q2 2026
$100.8 million
Research and development expenses for the second quarter of 2026
SG&A expenses Q2 2026
$51.5 million
Selling, general and administrative expenses for the second quarter of 2026
Cumulative AQVESME prescriptions
442
Cumulative AQVESME prescriptions for thalassemia written by June 30, 2026
Key Terms
Priority Review, PDUFA goal date, accelerated approval pathway, Risk Evaluation and Mitigation Strategy (REMS), +1 more
5 terms
Priority Review regulatory
"sNDA for mitapivat granted FDA Priority Review in sickle cell disease"
Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.
PDUFA goal date regulatory
"The PDUFA goal date for this sNDA is November 1, 2026"
The PDUFA goal date is the target deadline set by the U.S. Food and Drug Administration for completing its review of a new drug or biologic application. Investors watch it like a court date for a product: the outcome (approval, rejection, or request for more information) can sharply change a company’s revenue prospects and stock price, and the date gives a predictable event around which markets and planning can focus.
accelerated approval pathway regulatory
"sNDA, submitted under the FDA’s accelerated approval pathway"
The accelerated approval pathway is a process that allows new medicines to be approved more quickly based on early evidence that they may be effective, rather than waiting for full proof. This can help patients access promising treatments faster, but it also means ongoing studies are needed to confirm the benefits. For investors, it highlights potential faster market entry and earlier revenue opportunities, along with some uncertainty about long-term outcomes.
Risk Evaluation and Mitigation Strategy (REMS) regulatory
"prescriptions written by Risk Evaluation and Mitigation Strategy (REMS)-certified U.S. physicians"
A Risk Evaluation and Mitigation Strategy (REMS) is a formal safety program required by regulators for certain medicines or medical products to ensure benefits outweigh serious risks. It sets rules—such as training for prescribers, special distribution systems, or monitoring—to reduce harm. For investors, REMS can limit how widely and quickly a product can be sold, raise compliance costs, and affect legal risk, similar to how safety checks can slow and add expense to running a vehicle fleet.
polycythemia vera medical
"advance AG-236 into a Phase 2/3 development program in polycythemia vera"
A rare, long-term blood disorder in which the body makes too many red blood cells, thickening the blood and raising the risk of clots, bleeding, fatigue and other complications. Think of it like a faucet left partially open that slowly overfills a sink — the excess cells create strain and danger over time. Investors care because the condition drives demand for diagnostics, treatments and ongoing care, influences clinical trial and regulatory outcomes, and can affect revenue and costs for drugmakers, hospitals and insurers.
Earnings Snapshot
Net product revenue: $44.7 million
Quarter ended June 30, 2026
Net product revenue
$44.7 million
up from $12.5 million in the second quarter of 2025
Net loss
$100.7 million
improved from net loss of $112.0 million in the second quarter of 2025
Net loss per share, basic and diluted
$1.69
compared with $1.93 in the second quarter of 2025
Cash, cash equivalents and marketable securities
$964.8 million
down from $1.2 billion as of December 31, 2025
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Agios (AGIO) revenues and net loss for Q2 2026?
Agios reported Q2 2026 net product revenue of $44.7 million, up from $12.5 million in Q2 2025. Net loss was $100.7 million, compared with $112.0 million a year earlier, with basic and diluted net loss per share of $1.69.
How did mitapivat (PYRUKYND and AQVESME) perform for Agios (AGIO) in Q2 2026?
Mitapivat delivered worldwide net revenues of $44.7 million in Q2 2026, including $40.9 million in U.S. and $3.8 million ex-U.S. revenue. The U.S. AQVESME launch in thalassemia generated 442 cumulative prescriptions written by REMS‑certified physicians by June 30, 2026.
What key regulatory milestones did Agios (AGIO) report for mitapivat?
Mitapivat’s sNDA in sickle cell disease received FDA Priority Review with a PDUFA goal date of November 1, 2026. In addition, PYRUKYND gained European Commission marketing authorization for thalassemia, and mitapivat is now approved for adults with thalassemia in the U.S., Saudi Arabia, UAE and EU.
What is the status of Agios (AGIO) pipeline programs AG-236 and AG-181?
Phase 1 data for AG-236 supported sustained hepcidin control, and Agios plans a Phase 2/3 program in polycythemia vera, starting Phase 2 in the second half of 2026. AG-181 entered a Phase 1b PKU trial, with data expected in the second half of 2026.
Why is Agios (AGIO) discontinuing tebapivat development?
Agios will not advance tebapivat in lower-risk myelodysplastic syndromes or sickle cell disease. Phase 2 studies showed biological activity but did not deliver sufficient clinical benefit or a differentiated profile versus other pyruvate kinase activators to meet the company’s advancement thresholds.
What is Agios (AGIO)’s cash position and how will it fund its plans?
Agios held $964.8 million in cash, cash equivalents and marketable securities at June 30, 2026, versus $1.2 billion at December 31, 2025. The company expects this, combined with anticipated product revenue and interest income, to support launches and advancement of its current pipeline.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 30, 2026
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code: (617 ) 649-8600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||
| Emerging growth company | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | |||||
| Item 2.02 | Results of Operations and Financial Condition. | ||||
On July 30, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended June 30, 2026 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits. | ||||
(d) Exhibits.
| Exhibit No. | Description | ||||
| 99.1 | Press release issued July 30, 2026 | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AGIOS PHARMACEUTICALS, INC. | ||||||||
Date: July 30, 2026 | By: | /s/ Brian Goff | ||||||
Brian Goff Chief Executive Officer | ||||||||
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
•Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025
•Strong U.S. commercial launch of AQVESME in thalassemia, with 442 cumulative prescriptions written as of June 30, 2026
•sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026
•Diversified and expanded late-stage pipeline with licensing of cevidoplenib for immune thrombocytopenia and advancement of AG-236 into Phase 2/3 development for polycythemia vera
•$964.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026; well capitalized to support commercial execution and pipeline advancement
CAMBRIDGE, Mass., July 30, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the second quarter ended June 30, 2026.
“Our second-quarter performance reflects continued execution across the key priorities that will drive sustainable growth for Agios: strong commercial momentum, pipeline diversification, and strategic portfolio discipline,” said Brian Goff, Chief Executive Officer, Agios. “We are encouraged by the ongoing U.S. commercial launch of AQVESME in thalassemia, which continues to see robust engagement from both physicians and patients. We also progressed mitapivat toward a potential new indication in sickle cell disease, highlighted by the FDA granting Priority Review for our sNDA. Beyond these milestones, we strengthened our hematology pipeline with the licensing of cevidoplenib and advancement of AG-236 into Phase 2/3 development, while maintaining disciplined capital allocation. Together, these achievements underscore our ability to deliver meaningful innovation for patients and long-term shareholder value.”
Second Quarter 2026 and Recent Corporate Highlights
•Mitapivat (PYRUKYND® and AQVESME™) Commercial Performance and Update –
o$40.9 million in U.S. net revenue and $3.8 million in ex-U.S. net revenue in the second quarter of 2026.
▪U.S. net revenue was driven by the U.S. commercial launch of AQVESME (mitapivat) in thalassemia in late January 2026.
▪Ex-U.S. net revenue reflected anticipated demand for PYRUKYND (mitapivat) in Europe following approval for thalassemia in May 2026, as well as continued, consistent early demand in Gulf Cooperation Council (GCC) countries.
oAs of June 30, 2026, 442 cumulative AQVESME prescriptions for thalassemia have been written by Risk Evaluation and Mitigation Strategy (REMS)-certified U.S. physicians.
•Business Development –
oAgios announced an agreement with Oscotec to license the exclusive global rights to cevidoplenib, a highly-selective, next-generation, oral spleen tyrosine kinase (SYK) inhibitor for immune thrombocytopenia (ITP). The addition of cevidoplenib diversifies Agios’ rare hematology portfolio and represents an opportunity to unlock up to $1.0 billion in peak U.S. sales potential in this indication.
oAgios expects to advance cevidoplenib into Phase 3 development for ITP in the first half of 2028, following completion of additional chemistry, manufacturing, and controls (CMC) development work.
Research and Development (R&D) Highlights
•Mitapivat (pyruvate kinase [PK] activator)
oThalassemia –
▪The European Commission (EC) granted marketing authorization for PYRUKYND in adults for the treatment of anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia, with an orphan medicinal product designation. With this decision, PYRUKYND is the only medicine approved in all European Union (EU) member states for this broad patient population.
▪Mitapivat is now approved for adults with thalassemia in the U.S., Saudi Arabia, United Arab Emirates, and EU.
oSickle Cell Disease –
▪The U.S. Food and Drug Administration (FDA) accepted Agios’ supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for this sNDA, submitted under the FDA’s accelerated approval pathway, is November 1, 2026.
▪Additionally, Agios dosed the first patient in the REIGNITE Phase 3 trial, the confirmatory clinical trial required to be conducted under the accelerated approval pathway. This global trial is designed to demonstrate the clinical benefit of mitapivat on reducing transfusion burden in patients with sickle cell disease aged 12 years or older.
▪Agios also filed for regulatory approval of mitapivat for sickle cell disease in Saudi Arabia.
•AG-236 (siRNA targeting TMPRSS6)
oPolycythemia Vera –
▪Results from Agios’ Phase 1 trial of AG-236 in healthy volunteers demonstrated sustained hepcidin control and effects on iron regulation biomarkers without the need for titration, supporting iron pathway modulation that can potentially address excess red blood cell production in polycythemia vera.
▪The data also indicate the potential for an up to every-six-month dosing schedule.
▪Based on these results, Agios will advance AG-236 into a Phase 2/3 development program in polycythemia vera, with initiation of the Phase 2 portion expected in the second half of 2026.
•AG-181 (phenylalanine hydroxylase [PAH] stabilizer)
oPhenylketonuria (PKU) –
▪Agios dosed the first patient in the Phase 1b trial evaluating the safety and tolerability of AG-181 in adults with PKU. Data from this trial are expected in the second half of 2026.
•Tebapivat (PK activator)
oLower-Risk Myelodysplastic Syndromes (LR-MDS) –
▪Agios announced that it will not advance tebapivat in LR-MDS following results from the company's Phase 2b trial. While tebapivat demonstrated evidence of biological activity, it did not demonstrate clinical benefit in a sufficient proportion of patients or any patient subgroup to meet the company's predefined threshold for advancement in LR-MDS.
oSickle Cell Disease –
▪Agios announced that it will not advance tebapivat in sickle cell disease following results from the company’s Phase 2 trial. The data further reinforced PK activation as a clinically validated mechanism in sickle cell disease; however, they did not demonstrate a sufficiently differentiated profile relative to other PK activators to justify continued development of tebapivat in this indication.
Second Quarter 2026 Financial Results
For the quarter ended June 30, 2026, net loss was $100.7 million, compared to net loss of $112.0 million for the quarter ended June 30, 2025.
•Net product revenue from U.S. sales of mitapivat (PYRUKYND and AQVESME) for the second quarter of 2026 was $40.9 million, compared to $12.2 million for the second quarter of 2025.
•Net product revenue from ex-U.S. sales of mitapivat (PYRUKYND) for the second quarter of 2026 was $3.8 million, compared to $0.3 million for the second quarter of 2025.
•Cost of sales for the second quarter of 2026 was $3.0 million.
•Research and Development (R&D) expenses were $100.8 million for the second quarter of 2026, compared to $91.9 million for the second quarter of 2025, driven primarily by the $25.0 million up-front payment associated with the agreement with Oscotec to license cevidoplenib.
•Selling, General and Administrative (SG&A) expenses were $51.5 million for the second quarter of 2026, compared to $45.9 million for the second quarter of 2025, due to an increase in activities related to the U.S. commercial launch of AQVESME in thalassemia.
•Cash, cash equivalents and marketable securities were $964.8 million as of June 30, 2026, compared to $1.2 billion as of December 31, 2025. Agios expects that its cash, cash equivalents and marketable securities, together with anticipated product revenue and interest income, will provide the financial independence to execute the U.S. commercial launch of AQVESME in thalassemia, prepare for the potential U.S. commercial launch of mitapivat in sickle cell disease, advance the company’s existing clinical programs, and opportunistically expand its pipeline through both internally- and externally-discovered assets.
Second Quarter 2026 Conference Call Information
Agios will host a conference call and live webcast today, July 30, 2026, at 8:00 a.m. ET to discuss the company’s second quarter 2026 financial results and recent business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.
About Agios: Fueled by Connections to Transform Rare Diseases™
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.
Available Information about Agios
To achieve broad dissemination, Agios may disclose information to the public through a variety of disclosure channels including press releases, SEC filings, and public conference calls and webcasts. Some of the information distributed through these disclosure channels may be considered material information. Investors and others should note that Agios plans to use its website (www.agios.com) as a distribution channel to announce and give notice of Agios’ upcoming events and presentations (including, but not limited to, presentations at medical or healthcare
conferences). Such information, which may be deemed material, will be available on the Investors section of the company’s website under the “Events & Presentations” tab. In addition, you may sign up to automatically receive email alerts about Agios’ upcoming events and presentations (“Calendar Alerts”) by visiting the “Email Alerts” option under the “IR Resources” tab of the Investors section of the company’s website and submitting your email address.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of PYRUKYND® (mitapivat), AQVESME™ (mitapivat), tebapivat, AG-236, AG-181 and cevidoplenib; Agios’ plans, strategies and expectations for its preclinical, clinical and commercial advancement of its drug development, including mitapivat, tebapivat, AG-236, AG-181 and cevidoplenib; Agios’ expectations for the review of marketing applications for mitapivat by regulatory agencies, including the FDA and European Commission; Agios’ strategic vision and goals; and the potential benefits of Agios’ strategic plans and focus. The words “anticipate,” “expect,” “goal,” “hope,” “milestone,” “plan,” “potential,” “possible,” “strategy,” “will,” “vision,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios’ product candidates will successfully continue. There can be no guarantee that any positive developments in Agios’ business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios’ ability to establish and maintain key collaborations; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of AG-236 and cevidoplenib, and the uncertainty of the timing of any such payments; uncertainty of the results and effectiveness of the use of Agios’ cash and cash equivalents; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios’ public filings with the Securities
and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
| Consolidated Balance Sheet Data | ||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||
| June 30, 2026 | December 31, 2025 | |||||||||||||||||||
| Cash, cash equivalents, and marketable securities | $ | 964,830 | $ | 1,164,438 | ||||||||||||||||
| Accounts receivable, net | 20,112 | 10,577 | ||||||||||||||||||
| Inventory* | 35,752 | 32,920 | ||||||||||||||||||
| Total assets | 1,108,424 | 1,297,225 | ||||||||||||||||||
| Stockholders' equity | 1,026,021 | 1,193,114 | ||||||||||||||||||
| *June 30, 2026 balance includes $5.6 million of long-term inventory included in other non-current assets within our condensed consolidated balance sheets. | ||||||||||||||||||||
| Consolidated Statements of Operations Data | |||||||||||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||||||||||
| (Unaudited) | |||||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||
| Product revenue, net | $ | 44,745 | $ | 12,455 | $ | 65,491 | $ | 21,181 | |||||||||||||||
| Total revenue | 44,745 | 12,455 | 65,491 | 21,181 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Cost of sales | $ | 2,996 | $ | 1,702 | $ | 4,315 | $ | 2,787 | |||||||||||||||
| Research and development | 100,754 | 91,940 | 181,902 | 164,683 | |||||||||||||||||||
| Selling, general and administrative | 51,547 | 45,869 | 99,851 | 87,396 | |||||||||||||||||||
| Total operating expenses | 155,297 | 139,511 | 286,068 | 254,866 | |||||||||||||||||||
| Loss from operations | (110,552) | (127,056) | (220,577) | (233,685) | |||||||||||||||||||
| Interest income, net | 9,730 | 14,513 | 20,525 | 30,600 | |||||||||||||||||||
| Other income, net | 119 | 523 | 238 | 1,776 | |||||||||||||||||||
| Net loss | $ | (100,703) | $ | (112,020) | $ | (199,814) | $ | (201,309) | |||||||||||||||
| Net loss per share - basic and diluted | $ | (1.69) | $ | (1.93) | $ | (3.38) | $ | (3.49) | |||||||||||||||
| Weighted-average number of common shares used in computing net loss per share – basic and diluted | 59,488,871 | 57,932,576 | 59,137,508 | 57,697,193 | |||||||||||||||||||
Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
morgan.sanford@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
eamonn.nolan@agios.com